Lipocine Inc Expected to Earn FY2017 Earnings of ($1.17) Per Share (LPCN)
Lipocine Inc (NASDAQ:LPCN) – Stock analysts at Zacks Investment Research raised their FY2017 EPS estimates for Lipocine in a research note issued on Thursday. Zacks Investment Research analyst J. Vandermosten now forecasts that the specialty pharmaceutical company will earn ($1.17) per share for the year, up from their prior forecast of ($1.39). Zacks Investment Research also issued estimates for Lipocine’s FY2019 earnings at $2.12 EPS.
Other research analysts have also recently issued reports about the stock. HC Wainwright reaffirmed a “buy” rating and issued a $25.00 target price on shares of Lipocine in a report on Wednesday, April 26th. Canaccord Genuity set a $10.00 target price on shares of Lipocine and gave the stock a “buy” rating in a report on Monday, April 24th.
COPYRIGHT VIOLATION WARNING: “Lipocine Inc Expected to Earn FY2017 Earnings of ($1.17) Per Share (LPCN)” was posted by American Banking News and is owned by of American Banking News. If you are viewing this report on another site, it was illegally copied and republished in violation of United States and international copyright & trademark legislation. The correct version of this report can be read at https://www.americanbankingnews.com/2017/05/15/lipocine-inc-expected-to-earn-fy2017-earnings-of-1-17-per-share-lpcn.html.
Shares of Lipocine (NASDAQ:LPCN) opened at 3.65 on Monday. The firm’s market cap is $70.30 million. Lipocine has a 12-month low of $2.51 and a 12-month high of $9.59. The company has a 50 day moving average of $3.91 and a 200-day moving average of $3.74.
Lipocine (NASDAQ:LPCN) last posted its earnings results on Monday, May 8th. The specialty pharmaceutical company reported ($0.26) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.30) by $0.04.
A number of hedge funds and other institutional investors have recently modified their holdings of LPCN. Teachers Advisors LLC boosted its position in shares of Lipocine by 26.4% in the fourth quarter. Teachers Advisors LLC now owns 32,874 shares of the specialty pharmaceutical company’s stock valued at $121,000 after buying an additional 6,869 shares during the period. Wells Fargo & Company MN purchased a new position in shares of Lipocine during the third quarter valued at about $122,000. KCG Holdings Inc. boosted its position in shares of Lipocine by 27.4% in the first quarter. KCG Holdings Inc. now owns 33,537 shares of the specialty pharmaceutical company’s stock valued at $131,000 after buying an additional 7,219 shares during the period. Parametric Portfolio Associates LLC boosted its position in shares of Lipocine by 27.1% in the first quarter. Parametric Portfolio Associates LLC now owns 58,739 shares of the specialty pharmaceutical company’s stock valued at $229,000 after buying an additional 12,518 shares during the period. Finally, Bank of New York Mellon Corp boosted its position in shares of Lipocine by 7.1% in the first quarter. Bank of New York Mellon Corp now owns 92,979 shares of the specialty pharmaceutical company’s stock valued at $362,000 after buying an additional 6,191 shares during the period. 45.02% of the stock is owned by institutional investors and hedge funds.
Lipocine Inc is a specialty pharmaceutical company. The Company is focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. Its primary development programs are based on oral delivery solutions for bioavailable drugs.
Receive News & Ratings for Lipocine Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lipocine Inc and related companies with MarketBeat.com's FREE daily email newsletter.